Samsung Biologics appointed John Rim as the new chief executive officer to replace former-CEO Kim Tae-han. Rim has been with Samsung Biologics since 2018, where his first role was as executive vice president. His responsibilities had included overseeing the operations of contract manufacturing and investor relations.